⚖ Head-to-Head · Dual vs Triple Agonist

Tirzepatide vs Retatrutide

Mechanism, half-life, dosing & research status compared side-by-side.

Tirzepatide
Metabolic / Dual Incretin Agonist
Approved (T2D 2022, obesity 2023)
GLP-1 AgonistGIP AgonistFDA ApprovedWeight ManagementMetabolic
Tirzepatide is a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed by Eli Lilly. By simultaneously activating both incretin receptors, t…
Full Tirzepatide profile →
Retatrutide
Metabolic / Triple Incretin Agonist
Not approved; Phase 3 complete for obesity, BLA submission planned
GLP-1 AgonistGIP AgonistGlucagon AgonistWeight ManagementMetabolicPhase 3
Retatrutide is a first-in-class triple receptor agonist developed by Eli Lilly that simultaneously activates GLP-1, GIP, and glucagon receptors. By adding glucagon receptor activity to the dual incretin mechanism of tirz…
Full Retatrutide profile →
Technical Specs Comparison
MetricTirzepatideRetatrutide
Research Status FDA Approved Phase 3 Complete (Obesity); BLA Planned
Molecular Weight 4813.47 Da ~4.4 kDa
Half-Life ~120 hours (5 days) ~6 days
Peak Time 8-72 hours post-injection 48-96 hours post-injection
Typical Dose 2.5-15 mg/week 4-12 mg/week (Phase 3 TRIUMPH-1 dose range)
Frequency Once weekly Once weekly
Route Subcutaneous injection Subcutaneous injection
Amino Acids 39 36
WADA Status Not listed Not listed
FDA Status Approved (T2D 2022, obesity 2023) Not approved; Phase 3 complete for obesity, BLA submission planned
Stack Compatibility & Key Differences
Tirzepatide has FDA approval; Retatrutide is research-only.
PK Plotter · Visualize plasma levels over time
Plot Tirzepatide → Plot Retatrutide →
Frequently Asked Questions
What is the difference between Tirzepatide and Retatrutide?
Tirzepatide: Tirzepatide is a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed by Eli Lilly. By simultaneously activating both incretin receptors, t… Retatrutide: Retatrutide is a first-in-class triple receptor agonist developed by Eli Lilly that simultaneously activates GLP-1, GIP, and glucagon receptors. By adding glucagon receptor activity to the dual incretin mechanism of tirz…
Can you stack Tirzepatide and Retatrutide?
Tirzepatide has FDA approval; Retatrutide is research-only.
Which has a longer half-life, Tirzepatide or Retatrutide?
Tirzepatide half-life: ~120 hours (5 days). Retatrutide half-life: ~6 days.
✓
Verified Scientific Data
All specifications on this page are sourced from peer-reviewed literature and primary research. Half-life values, dosing ranges, and mechanism data are cross-referenced against published studies. Last audited 2026-10-05.
● Peer-reviewed sources ● Audit timestamp: 2026-10-05 ● Data version: ASCEND Wiki 2026
Data sourced from ASCEND Wiki · Tirzepatide profile · Retatrutide profile · All comparisons
Ready to calculate your exact draw volume?
Enter your vial size and BAC water to get precise IU markings for any dose.
Calculate Tirzepatide dose → Calculate Retatrutide dose →